Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2008

01.12.2008 | Laboratory and Translational Research

The Penetratin Sequence in the Anticancer PNC-28 Peptide Causes Tumor Cell Necrosis Rather Than Apoptosis of Human Pancreatic Cancer Cells

verfasst von: Wilbur B. Bowne, MD, Kelley A. Sookraj, MD, Michael Vishnevetsky, Victor Adler, MD, PhD, Ehsan Sarafraz-Yazdi, MS, Sunming Lou, PhD, Jesco Koenke, MS, Vadim Shteyler, Kamran Ikram, MD, Michael Harding, Martin H. Bluth, MD, PhD, Mou Ng, PhD, Paul W. Brandt-Rauf, MD, Raqibul Hannan, PhD, Stephan Bradu, MD, PhD, Michael E. Zenilman, MD, Josef Michl, MD, Matthew R. Pincus, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

PNC-27 and PNC-28 are p53-derived peptides from the human double minute (hdm-2) binding domain attached to penetratin. These peptides induce tumor cell necrosis of cancer cells, but not normal cells. The anticancer activity and mechanism of PNC-28 (p53 aa17–26-penetratin) was specifically studied against human pancreatic cancer.

Methods

MiaPaCa-2 cells were treated with PNC-28. Necrosis was determined by measuring lactate dehydrogenase (LDH) and apoptosis as assayed for measuring elevation of proapoptotic proteins. PNC-29, an unrelated peptide, and hdm-2-binding domain p53 aa12-26 without penetratin (PNC-26) were used as controls. Since there is evidence that penetratin is required for tumor cell necrosis, we tested “naked” p53 peptide without penetratin by transfecting a plasmid that encodes p53 aa17–26 segment of PNC-28 into MiaPaCa-2 and an untransformed rat pancreatic acinar cell line, BMRPA1. Time-lapse electron microscopy was employed to further elucidate anticancer mechanism.

Results

Treatment with PNC-28 does not result in the elevation of proapoptotic proteins found in p53-induced apoptosis, but elicits rapid release of LDH, indicative of tumor cell necrosis. Accordingly, we observed membrane pore formation and dose-dependent killing. In direct contrast, transfected MiaPaCa-2 cells underwent apoptosis, and not necrosis, as evidenced by expression of high levels of caspases-3 and 7 and annexin V with background levels of LDH.

Conclusion

These results suggest that PNC-28 may be effective in treating human pancreatic cancer. The penetratin sequence appears to be responsible for the fundamental change in the mechanism of action, inducing rapid necrosis initiated by membrane pore formation. Cancer cell death by apoptosis was observed in the absence of penetratin.
Literatur
1.
Zurück zum Zitat Kanovsky M, Raffo A, Drew L et al. Peptides from the amino terminal mdm-2 binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA 2001; 98:12438–43PubMedCrossRef Kanovsky M, Raffo A, Drew L et al. Peptides from the amino terminal mdm-2 binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA 2001; 98:12438–43PubMedCrossRef
2.
Zurück zum Zitat Do TN, Rosal RV, Drew L et al. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the mdm-2 binding site. Oncogene 2003; 22:1431–44PubMedCrossRef Do TN, Rosal RV, Drew L et al. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the mdm-2 binding site. Oncogene 2003; 22:1431–44PubMedCrossRef
3.
Zurück zum Zitat Pincus MR, Michl J, Bowne W et al. Anti-Cancer Peptides from the ras-p21 and p53 Proteins. Research Advances in Cancer. Mohan RM (ed). Global Research Network, Kerala, India, pp 65–90, 2007 Pincus MR, Michl J, Bowne W et al. Anti-Cancer Peptides from the ras-p21 and p53 Proteins. Research Advances in Cancer. Mohan RM (ed). Global Research Network, Kerala, India, pp 65–90, 2007
4.
Zurück zum Zitat Rosal R, Pincus MR, Brandt-Rauf PW et al. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry 2004; 43:1754–861CrossRef Rosal R, Pincus MR, Brandt-Rauf PW et al. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry 2004; 43:1754–861CrossRef
5.
Zurück zum Zitat Rosal R, Brandt-Rauf PW, Pincus MR et al. The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Devel Rev 2004; 57:653–60CrossRef Rosal R, Brandt-Rauf PW, Pincus MR et al. The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Devel Rev 2004; 57:653–60CrossRef
6.
Zurück zum Zitat Michl J, Scharf B, Schmidt A et al. PNC-28, a p53 peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer 2006; 119:1577–85PubMedCrossRef Michl J, Scharf B, Schmidt A et al. PNC-28, a p53 peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer 2006; 119:1577–85PubMedCrossRef
7.
Zurück zum Zitat Picksley SM, Spicer JF, Barnes DM et al. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Acta Oncol 1996; 35:429–34PubMedCrossRef Picksley SM, Spicer JF, Barnes DM et al. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Acta Oncol 1996; 35:429–34PubMedCrossRef
8.
Zurück zum Zitat Bottger V, Bottger A, Howard SF et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996; 13:2141–7PubMed Bottger V, Bottger A, Howard SF et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996; 13:2141–7PubMed
9.
Zurück zum Zitat Wasylyk C, Salvi R, Argentini M et al. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999; 18:1921–34PubMedCrossRef Wasylyk C, Salvi R, Argentini M et al. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999; 18:1921–34PubMedCrossRef
10.
Zurück zum Zitat Chene P, Fuchs J, Carena I et al. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett 2002; 529:293–7PubMedCrossRef Chene P, Fuchs J, Carena I et al. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett 2002; 529:293–7PubMedCrossRef
11.
Zurück zum Zitat Garcia-Echeverria C, Furet P, Chene P. Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction. Bioorg Med Chem Lett 2001; 11:2161–4PubMedCrossRef Garcia-Echeverria C, Furet P, Chene P. Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction. Bioorg Med Chem Lett 2001; 11:2161–4PubMedCrossRef
12.
Zurück zum Zitat Harbour JW, Worley L, Ma D et al. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol 2002; 120:1341–6PubMed Harbour JW, Worley L, Ma D et al. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol 2002; 120:1341–6PubMed
13.
Zurück zum Zitat Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: CSHL, 2001 Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: CSHL, 2001
14.
Zurück zum Zitat Kanovsky M, Michl J, Botzolaki G et al. Peptides, designed from molecular modeling studies of the ras-p21 protein, induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth. Cancer Chemother Pharmacol 2003; 52:202–8PubMedCrossRef Kanovsky M, Michl J, Botzolaki G et al. Peptides, designed from molecular modeling studies of the ras-p21 protein, induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth. Cancer Chemother Pharmacol 2003; 52:202–8PubMedCrossRef
15.
Zurück zum Zitat van den Eijnde SM, Boshart L, Baehrecke EH et al. Cell surface exposure of phosphatidylserine during apoptosis is phylogenetically conserved. Apoptosis 1998; 3:9–16PubMedCrossRef van den Eijnde SM, Boshart L, Baehrecke EH et al. Cell surface exposure of phosphatidylserine during apoptosis is phylogenetically conserved. Apoptosis 1998; 3:9–16PubMedCrossRef
16.
Zurück zum Zitat Camus S, Higgins M, Lane D et al. Differences in the ubiquitination of p53 by mdm2 and the HPV protein E6. FEBS Lett 2003; 536:220–4PubMedCrossRef Camus S, Higgins M, Lane D et al. Differences in the ubiquitination of p53 by mdm2 and the HPV protein E6. FEBS Lett 2003; 536:220–4PubMedCrossRef
Metadaten
Titel
The Penetratin Sequence in the Anticancer PNC-28 Peptide Causes Tumor Cell Necrosis Rather Than Apoptosis of Human Pancreatic Cancer Cells
verfasst von
Wilbur B. Bowne, MD
Kelley A. Sookraj, MD
Michael Vishnevetsky
Victor Adler, MD, PhD
Ehsan Sarafraz-Yazdi, MS
Sunming Lou, PhD
Jesco Koenke, MS
Vadim Shteyler
Kamran Ikram, MD
Michael Harding
Martin H. Bluth, MD, PhD
Mou Ng, PhD
Paul W. Brandt-Rauf, MD
Raqibul Hannan, PhD
Stephan Bradu, MD, PhD
Michael E. Zenilman, MD
Josef Michl, MD
Matthew R. Pincus, MD, PhD
Publikationsdatum
01.12.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0147-0

Weitere Artikel der Ausgabe 12/2008

Annals of Surgical Oncology 12/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.